The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
 
Pasi Jänne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Blueprint Medicines; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Puma Biotechnology (Inst); Revolution Medicines (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
Expert Testimony - AstraZeneca
 
Willemijn Theelen
Research Funding - AstraZeneca (Inst); MSD (Inst); Regeneron (Inst)
 
Marina Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; IO Biotech; Janssen; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Novocure; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Janessa Laskin
Honoraria - AstraZeneca; Lilly; Pfizer; Roche Canada
Consulting or Advisory Role - Lilly; Pfizer; Takeda Science Foundation
Research Funding - Roche Canada (Inst)
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DAICHII SANKYO; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Firas Badin
Speakers' Bureau - Bristol-Myers Squibb/Pfizer; GE Healthcare; Jazz Pharmaceuticals; Lilly; Merck; Merck Serono; Regeneron
 
Lisenka Boom
No Relationships to Disclose
 
Carlos Aguado De La Rosa
Consulting or Advisory Role - AstraZeneca Canada; Bristol-Myers Squibb; Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre; Takeda
Other Relationship - AstraZeneca; Bristol-Myers Squibb; Mirati Therapeutics, a Bristol Myers Squibb company; MSD; Novartis; Regeneron
 
Izabela Chmielewska
Honoraria - Amgen; AstraZeneca; BMS; MSD
Travel, Accommodations, Expenses - MSD
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Novartis; Peervoice; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.”; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Gyula Ostoros
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche
Other Relationship - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche
 
Lauren Jimenez-Kurlander
Employment - Bristol-Myers Squibb
 
Cassie Lane
Employment - Bristol-Myers Squibb; Mirati Therapeutics, a Bristol Myers Squibb company
 
Archie Sachdeva
Employment - Bristol-Myers Squibb
 
Laura Eccles
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; D3 Bio; Daiichi Sankyo; GenomiCare; Hutchison MediPharma; Menarini; Mirati Therapeutics, a Bristol Myers Squibb company; Novartis; Pfizer; Roche; Simcere; Takeda; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); F. Hoffmann- La Roche (Inst); Hansoh (Inst); HenRui (Inst); Hutchison MediPharma (Inst)
Other Relationship - AstraZeneca; Hansoh; Roche